المؤلفون: Colombo, N., Lorusso, D., Monk, B.J., Slomovitz, B., Hasegawa, K., Nogueira-Rodrigues, A., Zale, M., Okpara, C.E., Barresi, G., McKenzie, J., Makker, V.

المساهمون: HonorHealth Research Institute, University of Arizona

المصدر: The oncologist

مصطلحات موضوعية: adverse reactions, endometrial cancer, lenvatinib, pembrolizumab

Relation: Nicoletta Colombo, Domenica Lorusso, Bradley J Monk, Brian Slomovitz, Kosei Hasegawa, Angélica Nogueira-Rodrigues, Melissa Zale, Chinyere E Okpara, Gianmaria Barresi, Jodi McKenzie, Vicky Makker, Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab, The Oncologist, Volume 29, Issue 1, January 2024, Pages 25–35, https://doi.org/10.1093/oncolo/oyad201; http://hdl.handle.net/10150/672146; The oncologist

الاتاحة: http://hdl.handle.net/10150/672146
https://doi.org/10.1093/oncolo/oyad201

المؤلفون: Colombo, N, Lorusso, D, Monk, B, Slomovitz, B, Hasegawa, K, Nogueira-Rodrigues, A, Zale, M, Okpara, C, Barresi, G, Mckenzie, J, Makker, V, Colombo, Nicoletta, Lorusso, Domenica, Monk, Bradley J, Slomovitz, Brian, Hasegawa, Kosei, Nogueira-Rodrigues, Angélica, Zale, Melissa, Okpara, Chinyere E, Barresi, Gianmaria, McKenzie, Jodi, Makker, Vicky

مصطلحات الفهرس: adverse reaction, endometrial cancer, lenvatinib, pembrolizumab, info:eu-repo/semantics/article

URL: https://hdl.handle.net/10281/434280
info:eu-repo/semantics/altIdentifier/pmid/37523661
info:eu-repo/semantics/altIdentifier/wos/WOS:001039945300001
volume:29
issue:1
firstpage:25
lastpage:35
numberofpages:11
journal:THE ONCOLOGIST

المؤلفون: Colombo, N, Lorusso, D, Monk, B, Slomovitz, B, Hasegawa, K, Nogueira-Rodrigues, A, Zale, M, Okpara, C, Barresi, G, Mckenzie, J, Makker, V, Colombo N., Lorusso D., Monk B. J., Slomovitz B., Hasegawa K., Nogueira-Rodrigues A., Zale M., Okpara C. E., Barresi G., McKenzie J., Makker V.

مصطلحات الفهرس: adverse reaction, endometrial cancer, lenvatinib, pembrolizumab, info:eu-repo/semantics/article

URL: https://hdl.handle.net/10281/503261
volume:4
issue:12
firstpage:62
lastpage:75
numberofpages:14
journal:KLINICESKIJ RAZBOR V OBSEJ MEDICINE

المؤلفون: Colombo N., Lorusso D., Monk B. J., Slomovitz B., Hasegawa K., Nogueira-Rodrigues A., Zale M., Okpara C. E., Barresi G., McKenzie J., Makker V.

المساهمون: Colombo, N, Lorusso, D, Monk, B, Slomovitz, B, Hasegawa, K, Nogueira-Rodrigues, A, Zale, M, Okpara, C, Barresi, G, Mckenzie, J, Makker, V

مصطلحات موضوعية: adverse reaction, endometrial cancer, lenvatinib, pembrolizumab

وصف الملف: STAMPA

Relation: volume:4; issue:12; firstpage:62; lastpage:75; numberofpages:14; journal:KLINICESKIJ RAZBOR V OBSEJ MEDICINE; https://hdl.handle.net/10281/503261; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85187195853

الاتاحة: https://hdl.handle.net/10281/503261
https://doi.org/10.47407/kr2023.4.12.00333

المؤلفون: Moore K, Zale M, Moramarco ML

المصدر: RN; Aug98, Vol. 61 Issue 8, p36-40, 5p